{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:37:38Z","timestamp":1784889458635,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00432-022-03941-2","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T18:02:22Z","timestamp":1649527342000},"page":"1893-1901","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer"],"prefix":"10.1007","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8005-1745","authenticated-orcid":false,"given":"Naoki","family":"Shijubou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-5878","authenticated-orcid":false,"given":"Toshiyuki","family":"Sumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-4496","authenticated-orcid":false,"given":"Yuichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3900-8117","authenticated-orcid":false,"given":"Hisashi","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2523-6752","authenticated-orcid":false,"given":"Yuji","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-3084","authenticated-orcid":false,"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"key":"3941_CR1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/annonc\/mdz288","volume":"30","author":"EJ Aguilar","year":"2019","unstructured":"Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM (2019) Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol 30:1653\u20131659. https:\/\/doi.org\/10.1093\/annonc\/mdz288","journal-title":"Ann Oncol"},{"key":"3941_CR2","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1002\/cam4.2806","volume":"7","author":"K Amrane","year":"2020","unstructured":"Amrane K, Geier M, Corre R, L\u00e9na H, L\u00e9veiller G, Gadby F, Lamy R, Bizec JL, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R (2020) First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 \u226550% in a multicenter real-life cohort: the PEMBREIZH study. Cancer Med 7:2309\u20132316. https:\/\/doi.org\/10.1002\/cam4.2806","journal-title":"Cancer Med"},{"key":"3941_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","volume":"106","author":"SJ Bagley","year":"2017","unstructured":"Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson JC, Stonehouse-Lee S, Sherry VE, Gilbert E, Eaby-Sandy B, Mutale F, DiLullo G, Cohen RB, Vachani A, Langer CJ (2017) Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer 106:1\u20137. https:\/\/doi.org\/10.1016\/j.lungcan.2017.01.013","journal-title":"Lung Cancer"},{"key":"3941_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.amjsurg.2009.08.041","volume":"200","author":"I Bhatti","year":"2010","unstructured":"Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI (2010) Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 200:197\u2013203. https:\/\/doi.org\/10.1016\/j.amjsurg.2009.08.041","journal-title":"Am J Surg"},{"key":"3941_CR5","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1245\/s10434-015-4516-1","volume":"22","author":"AW Chan","year":"2015","unstructured":"Chan AW, Chan SL, Wong GL, Wong VW, Chong CC, Lai PB, Chan HL, To KF (2015) Prognostic nutritional index (PNI) predicts tumor recurrence of very early\/early stage hepatocellular carcinoma after surgical resection. Ann Surg Oncol 22:4138\u20134148. https:\/\/doi.org\/10.1245\/s10434-015-4516-1","journal-title":"Ann Surg Oncol"},{"key":"3941_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","volume":"7","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Bersanelli M, Buti S et al (2019) A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 7:57. https:\/\/doi.org\/10.1186\/s40425-019-0527-y","journal-title":"J Immunother Cancer"},{"key":"3941_CR7","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/s41598-020-58498-2","volume":"10","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Bozzetti F, Palumbo P et al (2020) Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: a multicenter real-life study. Sci Rep 10:1456. https:\/\/doi.org\/10.1038\/s41598-020-58498-2","journal-title":"Sci Rep"},{"key":"3941_CR8","doi-asserted-by":"publisher","first-page":"11369","DOI":"10.1038\/s41598-018-29825-5","volume":"8","author":"BA Derstine","year":"2018","unstructured":"Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC (2018) Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep 8:11369. https:\/\/doi.org\/10.1038\/s41598-018-29825-5","journal-title":"Sci Rep"},{"key":"3941_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"5","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 5:489\u2013495. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7","journal-title":"Lancet Oncol"},{"key":"3941_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon KC, Glass DJ, Guttridge DC (2012) Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16:153\u2013166. https:\/\/doi.org\/10.1016\/j.cmet.2012.06.011","journal-title":"Cell Metab"},{"key":"3941_CR11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","volume":"36","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC, Leming P, Geese WJ, Yoon D, Li A, Brahmer J (2018) Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol 36:1675\u20131684. https:\/\/doi.org\/10.1200\/JCO.2017.77.0412","journal-title":"J Clin Oncol"},{"key":"3941_CR12","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.nut.2016.04.003","volume":"32","author":"Y Hamaguchi","year":"2016","unstructured":"Hamaguchi Y, Kaido T, Okumura S, Kobayashi A, Hammad A, Tamai Y, Inagaki N, Uemoto S (2016) Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. Nutrition 32:1200\u20131205. https:\/\/doi.org\/10.1016\/j.nut.2016.04.003","journal-title":"Nutrition"},{"key":"3941_CR13","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1007\/s00268-016-3491-4","volume":"40","author":"K Haruki","year":"2016","unstructured":"Haruki K, Shiba H, Shirai Y, Horiuchi T, Iwase R, Fujiwara Y, Furukawa K, Misawa T, Yanaga K (2016) The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg 40:2254\u20132260. https:\/\/doi.org\/10.1007\/s00268-016-3491-4","journal-title":"World J Surg"},{"key":"3941_CR14","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, Felip E, P\u00e9rez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"3941_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2407-13-158","volume":"13","author":"SH Jafri","year":"2013","unstructured":"Jafri SH, Shi R, Mills G (2013) Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer 13:158. https:\/\/doi.org\/10.1186\/1471-2407-13-158","journal-title":"BMC Cancer"},{"key":"3941_CR16","doi-asserted-by":"publisher","first-page":"e001674","DOI":"10.1136\/jitc-2020-001674","volume":"8","author":"P Johannet","year":"2020","unstructured":"Johannet P, Sawyers A, Qian Y, Kozloff S, Gulati N, Donnelly D, Zhong J, Osman I (2020) Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. J Immunother Cancer 8:e001674. https:\/\/doi.org\/10.1136\/jitc-2020-001674","journal-title":"J Immunother Cancer"},{"key":"3941_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"3941_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/bjs.7305","volume":"98","author":"M Kanda","year":"2011","unstructured":"Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S, Nakao A (2011) Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg 98:268\u2013274. https:\/\/doi.org\/10.1002\/bjs.7305","journal-title":"Br J Surg"},{"key":"3941_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K (2018) Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643\u201304). Cancer 124:606\u2013616. https:\/\/doi.org\/10.1002\/cncr.31128","journal-title":"Cancer"},{"key":"3941_CR20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1245\/s10434-014-4048-0","volume":"22","author":"A Kinoshita","year":"2015","unstructured":"Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M (2015) The C-reactive protein\/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol 22:803\u2013810. https:\/\/doi.org\/10.1245\/s10434-014-4048-0","journal-title":"Ann Surg Oncol"},{"key":"3941_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.febslet.2013.10.015","volume":"588","author":"C Kyi","year":"2014","unstructured":"Kyi C, Postow MA (2014) Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett 588:368\u2013376. https:\/\/doi.org\/10.1016\/j.febslet.2013.10.015","journal-title":"FEBS Lett"},{"key":"3941_CR22","doi-asserted-by":"publisher","first-page":"8201","DOI":"10.2147\/CMAR.S210958","volume":"11","author":"V Magri","year":"2019","unstructured":"Magri V, Gottfried T, Di Segni M, Urban D, Peled M, Daher S, Stoff R, Bar J, Onn A (2019) Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients. Cancer Manag Res 11:8201\u20138207. https:\/\/doi.org\/10.2147\/CMAR.S210958","journal-title":"Cancer Manag Res"},{"key":"3941_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JCO.2014.56.1894","volume":"33","author":"L Martin","year":"2015","unstructured":"Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, Strasser F, Thoresen L, Jagoe RT, Chasen M, Lundholm K, Bosaeus I, Fearon KH, Baracos VE (2015) Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 33:90\u201399. https:\/\/doi.org\/10.1200\/JCO.2014.56.1894","journal-title":"J Clin Oncol"},{"key":"3941_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.21037\/atm.2017.08.04","volume":"5","author":"M Mathew","year":"2017","unstructured":"Mathew M, Safyan RA, Shu CA (2017) PD-L1 as a biomarker in NSCLC: challenges and future directions. Ann Transl Med 5:375. https:\/\/doi.org\/10.21037\/atm.2017.08.04","journal-title":"Ann Transl Med"},{"issue":"10183","key":"3941_CR25","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush D, Lopes G, KEYNOTE-042 Investigators (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393(10183):1819\u20131830. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"3941_CR26","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jhep.2012.08.017","volume":"58","author":"T Motomura","year":"2013","unstructured":"Motomura T, Shirabe K, Mano Y, Muto J, Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y (2013) Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 58:58\u201364. https:\/\/doi.org\/10.1016\/j.jhep.2012.08.017","journal-title":"J Hepatol"},{"key":"3941_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw KW, Goldberg MS, Konstantinopoulos PA, D\u2019Andrea AD (2017) DNA damage and repair biomarkers of immunotherapy response. Cancer Discov 7:675\u2013693. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0226","journal-title":"Cancer Discov"},{"key":"3941_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40425-019-0512-5","volume":"7","author":"GS Naik","year":"2019","unstructured":"Naik GS, Waikar SS, Johnson AEW, Buchbinder EI, Haq R, Hodi FS, Schoenfeld JD, Ott PA (2019) Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer 7:89. https:\/\/doi.org\/10.1186\/s40425-019-0512-5","journal-title":"J Immunother Cancer"},{"key":"3941_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3390\/ph13110373","volume":"13","author":"NJ Nasser","year":"2020","unstructured":"Nasser NJ, Gorenberg M, Agbarya A (2020) First line immunotherapy for non-small cell lung cancer. Pharmaceuticals (Basel) 13:373. https:\/\/doi.org\/10.3390\/ph13110373","journal-title":"Pharmaceuticals (Basel)"},{"key":"3941_CR30","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, KEYNOTE-024 Investigators (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"3941_CR31","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leal TA, Riess JW, Jensen E, Zhao B, Pietanza MC, Brahmer JR (2021) Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with Pd-L1 tumor proportion score \u2265 50. J Clin Oncol 39:2339\u20132349. https:\/\/doi.org\/10.1200\/JCO.21.00174","journal-title":"J Clin Oncol"},{"key":"3941_CR32","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"key":"3941_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","volume":"143","author":"B Roch","year":"2020","unstructured":"Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures JP, Pujol JL, Bommart S (2020) Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer 143:19\u201326. https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.003","journal-title":"Lung Cancer"},{"key":"3941_CR34","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA (2020) Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov 10:1808\u20131825. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0522","journal-title":"Cancer Discov"},{"key":"3941_CR35","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1245\/s10434-011-1754-8","volume":"18","author":"RZ Sharaiha","year":"2011","unstructured":"Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, Altorki NK, Abrams JA (2011) Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol 18:3362\u20133369. https:\/\/doi.org\/10.1245\/s10434-011-1754-8","journal-title":"Ann Surg Oncol"},{"key":"3941_CR36","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1007\/s12325-020-01516-6","volume":"37","author":"M Shibata","year":"2020","unstructured":"Shibata M, Fukahori M, Kasamatsu E, Machii K, Hamauchi S (2020) A retrospective cohort study to investigate the incidence of cachexia during chemotherapy in patients with colorectal cancer. Adv Ther 37:5010\u20135022. https:\/\/doi.org\/10.1007\/s12325-020-01516-6","journal-title":"Adv Ther"},{"key":"3941_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/cam4.1234","volume":"7","author":"T Shiroyama","year":"2018","unstructured":"Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T (2018) Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med 7:13\u201320. https:\/\/doi.org\/10.1002\/cam4.1234","journal-title":"Cancer Med"},{"key":"3941_CR38","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1007\/s00520-016-3156-8","volume":"24","author":"K Takayama","year":"2016","unstructured":"Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O, Takeda Y, Aoe K, Kim YH, Yokota S, Tabeta H, Tomii K, Ohashi Y, Eguchi K, Watanabe K (2016) Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Support Care Cancer 24:3473\u20133480. https:\/\/doi.org\/10.1007\/s00520-016-3156-8","journal-title":"Support Care Cancer"},{"key":"3941_CR39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17:519\u2013531. https:\/\/doi.org\/10.1016\/S1470-2045(15)00558-6","journal-title":"Lancet Oncol"},{"key":"3941_CR40","doi-asserted-by":"publisher","first-page":"6491","DOI":"10.21873\/anticanres.11248","volume":"36","author":"Y Toiyama","year":"2016","unstructured":"Toiyama Y, Shimura T, Yasuda H, Fujikawa H, Okita Y, Kobayashi M, Ohi M, Yoshiyama S, Hiro J, Araki T, Inoue Y, Mohri Y, Kusunoki M (2016) Clinical burden of C-reactive protein\/albumin ratio before curative surgery for patients with gastric cancer. Anticancer Res 36:6491\u20136498. https:\/\/doi.org\/10.21873\/anticanres.11248","journal-title":"Anticancer Res"},{"key":"3941_CR41","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/jso.21725","volume":"102","author":"H Ubukata","year":"2010","unstructured":"Ubukata H, Motohashi G, Tabuchi T, Nagata H, Konishi S, Tabuchi T (2010) Evaluations of interferon-\u03b3\/interleukin-4 ratio and neutrophil\/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol 102:742\u2013747. https:\/\/doi.org\/10.1002\/jso.21725","journal-title":"J Surg Oncol"},{"key":"3941_CR42","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jso.20329","volume":"91","author":"SR Walsh","year":"2005","unstructured":"Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181\u2013184. https:\/\/doi.org\/10.1002\/jso.20329","journal-title":"J Surg Oncol"},{"key":"3941_CR43","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12885-015-1379-6","volume":"15","author":"XL Wei","year":"2015","unstructured":"Wei XL, Wang FH, Zhang DS, Qiu MZ, Ren C, Jin Y, Zhou YX, Wang DS, He MM, Bai L, Wang F, Luo HY, Li YH, Xu RH (2015) A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein\/albumin ratio. BMC Cancer 15:350. https:\/\/doi.org\/10.1186\/s12885-015-1379-6","journal-title":"BMC Cancer"},{"key":"3941_CR44","doi-asserted-by":"publisher","first-page":"e126908","DOI":"10.1172\/jci.insight.126908","volume":"4","author":"M Yarchoan","year":"2019","unstructured":"Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru DA, Frampton GM, Jaffee EM (2019) PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4:e126908. https:\/\/doi.org\/10.1172\/jci.insight.126908","journal-title":"JCI Insight"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03941-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-03941-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-03941-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T04:04:38Z","timestamp":1658117078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-03941-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["3941"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-03941-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,9]]},"assertion":[{"value":"5 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This study was conducted with the approval of the Institutional Review Board (IRB) of Hakodate Goryokaku Hospital (No. 2021\u2013015), and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this was a retrospective study, the IRB waived the requirement for informed consent, but patient confidentiality was protected.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}